Farxiga®
Dapagliflozin is an SGLT2 inhibitor for diabetes, heart failure, and chronic kidney disease. Shown to reduce hospitalization for HF and slow CKD progression.
| Dosage Form | Oral Tablet (Film-Coated) |
| Strength | 5 mg, 10 mg |
| Storage | Store at 20–25°C. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
Type 2 diabetes; heart failure (HFrEF and HFpEF); chronic kidney disease.
Selectively inhibits SGLT2 in the kidney proximal tubule, reducing renal glucose reabsorption and producing osmotic diuresis with natriuresis, benefiting cardiovascular and renal outcomes.
Each Burrard Pharmaceuticals technology transfer package for Dapagliflozin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.